Actively Recruiting
Gut Microbiota and Prognostic Outcomes in Intracranial Arterial Stenosis Patients（GROW-ICAS）
Led by Nanjing First Hospital, Nanjing Medical University · Updated on 2025-07-25
500
Participants Needed
1
Research Sites
187 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
GROW-ICAS (Gut microBiota and prOgnostic Outcomes in IntraCranial Arterial Stenosis) is a prospective observational cohort study that enrolls patients with intracranial arterial stenosis to investigate the correlations between their gut microbiota, metabolomic, and transcriptomic profiles and three key clinical domains: functional outcomes, vascular plaque imaging characteristics, and post-stroke non-motor dysfunctions (including cognitive impairment, depression, anxiety, and fatigue).
CONDITIONS
Official Title
Gut Microbiota and Prognostic Outcomes in Intracranial Arterial Stenosis Patients（GROW-ICAS）
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 30-80 years
- Intracranial arterial stenosis confirmed by CTA, MRA, or DSA
- Local residency of at least 6 consecutive months
- Signed informed consent
You will not qualify if you...
- Tandem extracranial stenosis (≥50%) near the target intracranial vessel
- Non-atherosclerotic intracranial stenosis
- Endovascular treatment within 30 days before enrollment or planned within 6 months
- Intracranial hemorrhage within 90 days before enrollment
- Pre-existing intracranial tumor, cerebral aneurysm, or arteriovenous malformation
- Cardioembolic embolism
- Active bleeding or bleeding disorders
- Major surgery within 30 days before enrollment or planned within 6 months after enrollment
- Severe neurological deficits preventing independent living or dementia/psychiatric disorders hindering follow-up
- Pregnancy, lactation, or planned pregnancy
- Chronic inflammatory or autoimmune diseases
- Uncontrolled hypertension or diabetes
- Severe cardiac, liver, kidney problems, blood disorders, cancer, or life expectancy less than 1 year
- MRI contraindications
- History of depression, anxiety, or cognitive impairment requiring therapy
- Use of antibiotics, probiotics, glucocorticoids, or immunosuppressants within 1 month before enrollment
- Current or planned participation in other clinical trials
- Inability to cooperate due to psychiatric or emotional disorders
- Other reasons deemed ineligible by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Nanjing First Hospital, Nanjing Medical University
Nanjing, Jiangsu, China, 210006
Actively Recruiting
Research Team
J
Junshan Zhou
CONTACT
M
Mengmeng Gu
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here